RXRX vs. VCEL, PTCT, APGE, KYMR, ADMA, ACLX, BEAM, TWST, IMCR, and SANA
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Vericel (VCEL), PTC Therapeutics (PTCT), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), ADMA Biologics (ADMA), Arcellx (ACLX), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Immunocore (IMCR), and Sana Biotechnology (SANA). These companies are all part of the "medical" sector.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment.
Recursion Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.
89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Vericel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Vericel had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 11 mentions for Vericel and 10 mentions for Recursion Pharmaceuticals. Vericel's average media sentiment score of 0.48 beat Recursion Pharmaceuticals' score of 0.44 indicating that Vericel is being referred to more favorably in the news media.
Vericel received 315 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 62.22% of users gave Vericel an outperform vote while only 51.22% of users gave Recursion Pharmaceuticals an outperform vote.
Vericel has higher revenue and earnings than Recursion Pharmaceuticals. Vericel is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Recursion Pharmaceuticals presently has a consensus target price of $12.75, suggesting a potential upside of 35.35%. Vericel has a consensus target price of $46.80, suggesting a potential downside of 3.21%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Vericel.
Vericel has a net margin of 0.22% compared to Recursion Pharmaceuticals' net margin of -765.90%. Vericel's return on equity of 0.21% beat Recursion Pharmaceuticals' return on equity.
Summary
Vericel beats Recursion Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
